THALES
30.11.2022 16:01:47 CET | Business Wire | Press release
Thales today announced the launch of its CipherTrust Cloud Key Manager integration with the AWS External Key Store, a feature of the AWS Key Management Service announced at AWS re:Invent 2022. Following an increased call for enhanced sovereign controls amid growing regulatory requirements, the integration enables organisations to retain control of their encryption keys when migrating their sensitive data to the AWS cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005542/en/
©Thales
Developed with Thales since its inception, the AWS External Key Store combined with CipherTrust Cloud Key Manager offers organisations looking to move critical workloads to the cloud a way to maintain sovereign control of sensitive data throughout their digital transformation journey.
“We’ve had a strong technical collaboration with Thales on the development of the AWS External Key Store specification from the very beginning, in part due to their long history of expertise developing hardware security modules and key management services,” said Ken Beer, General Manager, Key Management Service at AWS. “The cloud has become a critical point of operation across businesses, and our combined expertise provides a way of helping organisations address specific needs and know they’re getting industry-best security controls in the process.”
According to the Thales 2022 Cloud Security Study, encryption is the number one choice to protect data in the cloud. However, only about one-third (29%) of respondents report total control of their keys to encrypted data in the cloud. User-controlled encryption and key management in hybrid IT are essential safeguards to enforce digital sovereignty in a modern data-driven world governed by privacy compliance mandates, regulated sectors, or general IT security recommendations such as the Shared Responsibility Model and the NIS2 Directive.
CipherTrust Cloud Key Manager ensures AWS External Key Store customers can satisfy these urgent regulatory requirements by leveraging strong encryption and data security methods that allow organisations to manage their data separately from the cloud service provider. Such a safeguard, also known as Hold Your Own Key (HYOK), enables organisations to maintain key ownership separate from the cloud data store.
“Varying data protection regulations across countries have presented a challenge for global organisations migrating to the cloud,” said Heleen Herselman, VP AWS Powerhouse at T-Systems Cloud Service. “The CipherTrust Cloud Key Manager simplifies this challenge and ensures we remain compliant while taking advantage of all the benefits of leveraging cloud services. The ability to lean on Thales’ solution has become especially important, as we, and other organisations, increasingly rely on multi-cloud environments.”
CipherTrust Cloud Key Manager is an industry-leading multi-cloud encryption key life cycle management solution that supports all major public cloud service providers. With a marked increase in multi-cloud adoption, this solution allows users to centralise key management across all clouds.
“This is the first integration on the market to solve a major pain point for AWS cloud customers: how can they utilise protected data in the AWS cloud while retaining encryption keys outside the cloud.” said Todd Moore, VP, Encryption Products at Thales. “As an industry leader in key management solutions, we are proud to offer an encryption solution that provides the ability to maintain external control of keys and cryptographic operations using those keys. CipherTrust Cloud Key Manager is at the forefront of advanced digital sovereignty. We’ll continue to introduce cutting-edge security and compliance features that support organisations in their digital transformation journeys.”
The Thales CipherTrust Cloud Key Manager integration for AWS External Key Store is available today. For more information, visit our landing page.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
